Literature DB >> 3277436

A double-masked comparison of carteolol and timolol in ocular hypertension.

B Scoville1, B Mueller, B G White, G K Krieglstein.   

Abstract

We performed a double-masked study in which 98 patients with ocular hypertension who had been previously treated with timolol received either timolol 0.25% or carteolol 1%, a beta-blocker with intrinsic sympathomimetic activity. The drugs were administered topically twice daily for one month after a one-week washout period. Intraocular pressure was measured at baseline and after one and four weeks of treatment. The appearance of the fundus, external eye, visual fields, tear secretion, blood pressure, and pulse were recorded. Adverse symptoms were elicited using a menu-type questionnaire and an overall judgment of therapy was recorded. Carteolol was as effective as timolol in reducing intraocular pressure. There were significantly fewer patients reporting adverse events overall (P = .019), and eye irritation specifically (P = .02), in the group treated with carteolol.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277436     DOI: 10.1016/0002-9394(88)90178-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

Review 1.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

2.  Ocular hypotensive efficacy and safety of once daily carteolol alginate.

Authors:  P Demailly; C Allaire; C Trinquand
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

Review 3.  Management of glaucoma: focus on pharmacological therapy.

Authors:  Robert E Marquis; Jess T Whitson
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1992 Jan-Feb       Impact factor: 3.923

Review 5.  Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.

Authors:  Sheridan Henness; Tracy Swainston Harrison; Gillian M Keating
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma.

Authors:  W C Stewart; M B Shields; R C Allen; R A Lewis; J S Cohen; H D Hoskins; J N Hetherington; R L Bahr; J E Noblin; J T Delehanty
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

7.  Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination.

Authors:  Kenji Inoue; Hua Piao; Mayumi Iwasa; Kyoko Ishida; Goji Tomita
Journal:  Clin Ophthalmol       Date:  2020-05-04

8.  Association between topical β-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database.

Authors:  Ai Kido; Masahiro Miyake; Tadamichi Akagi; Hanako Ohashi Ikeda; Takanori Kameda; Kenji Suda; Tomoko Hasegawa; Shusuke Hiragi; Satomi Yoshida; Akitaka Tsujikawa; Hiroshi Tamura; Koji Kawakami
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-09       Impact factor: 3.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.